Drugs / Td-IPV
Trials 0
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Comparator or background therapy1 trial | ||||||
| Phase 4 | NCT06903221 Comparator | Oct 2024 → Oct 2026 expected | pertussis | Radboud University Medical Center | Active not recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Td-IPV | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06903221 ↗ |
| Modality | Vaccine | “Participants will be vaccinated with Tdap-IPV or Td-IPV” NCT06903221 ↗ |
| Route | Intramuscular | “intramuscular injection” NCT06903221 ↗ |